Growing cases of falls and knee cartilage injuries is a prime factor that is expected to propel the growth of the Europe allogeneic human chondrocyte market over the forecast period. According to the article published in the British Medical Journal (BMJ Journal) February 2020, the incidence of falls in European countries were as follows in 2017: in the Western European region, 13,840 per 100,000 population seek medical treatment for a fall-related injury, of which 7,594/100,000 are from Greece and 19,796 are from Norway. Moreover, growing cases of musculoskeletal system disorders are again fostering the growth of the market. According to the State of Musculoskeletal Health, 2019 report by the Versus Arthritis, the prevalence of musculoskeletal conditions in the U.K. in 2017.
On the other hand, the high cost of the research & development which significantly affect the development process is expected to hinder the g
Key players engaged in the Europe allogeneic human chondrocyte market are Kolon TissueGene, Inc. and ISTO Technologies Inc.
Allogeneic Human Chondrocyte (AHCC) therapy is an alternative form of treatment for osteoarthritis. It is considered a tissue-based approach and not a medication. In contrast to the traditional approach of administration of steroids or non-steroidal anti-inflammatory drugs (NSAIDs), Allogenec (AHCC) uses stem cells taken from the bone marrow.
Read More: https://coherentmarketorientedblogs.blogspot.com/2021/07/the-prevalence-of-musculoskeletal.html
